http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Hee Jun Cho ),( Byung Moo Oh ),( Jong-tae Kim ),( Jeewon Lim ),( Sang Yoon Park ),( Yo Sep Hwang ),( Kyoung Eun Baek ),( Bo-yeon Kim ),( Inpyo Choi ),( Hee Gu Lee ) 한국미생물 · 생명공학회 2019 Journal of microbiology and biotechnology Vol.29 No.2
Interleukin-21 is a common γ-chain cytokine that controls the immune responses of B cells, T cells, and natural killer cells. Targeting IL-21 to strengthen the immune system is promising for the development of vaccines as well as anti-infection and anti-tumor therapies. However, the practical application of IL-21 is limited by the high production cost. In this study, we improved IL-21 production by codon optimization and selection of appropriate signal peptide in CHO-K1 cells. Codon-optimized or non-optimized human IL-21 was stably transfected into CHO-K1 cells. IL-21 expression was 10-fold higher for codon-optimized than non-optimized IL-21. We fused five different signal peptides to codon-optimized mature IL-21 and evaluated their effect on IL-21 production. The best result (a 3-fold increase) was obtained using a signal peptide derived from human azurocidin. Furthermore, codon-optimized IL-21 containing the azurocidin signal peptide promoted IFN-γ secretion and STAT3 phosphorylation in NK-92 cells similar to codon-optimized IL-21 containing original signal peptide. Collectively, these results indicate that codon optimization and azurocidin signal peptides provide an efficient approach for the high-level production of IL-21 as a biopharmaceutical.
Cho, Min Soo,Kim, Min-Seok,Lee, Sang Eun,Choi, Hyo-In,Lee, Jung-Bok,Cho, Hyun-Jai,Lee, Hae-Young,Choi, Jin-Oh,Jeon, Eun-Seok,Hwang, Kyung-Kuk,Chae, Shung Chul,Baek, Sang Hong,Kang, Seok-Min,Choi, Dong Elsevier 2018 The Canadian journal of cardiology Vol.34 No.9
<P>Conclusions: Pre-discharge BB initiation is associated with better clinical outcomes after severe acute decompensated heart failure episodes requiring inotropic therapy.</P>
Application of Perfluoropolymethylisopropyl Ether to Long Wearing Lipstick
( Sang-je Kim ),( Dong-uk Shin ),( Phan-gu Cho ),( Jae-gak Han ),( Jae-hyung Lim ),( Baek-sun Ahn ),( Chul-hee Jung ),( Gue-sam Lee ),( Won-sun Oh ),( Hyun-kwan Jung ),( Iio-yeun Kim ) 대한화장품학회 1997 대한화장품학회지 Vol.23 No.3
lt has been used chat fluorinated compounds could be applied to Make-up products. lt is that fluorinated compounds are hydropliobiciry, lipopliobiciry and lioinophobicitv. These fluorinated compounds are reported ro form a highly prorecrive and effective film againsr most aggressive chemical and physical agents. In this study we made a success to formulate the new type of lipstick using perfluoropolymerhylisopropylether (PPIH, MW- 650. commercial name - Fomblin HC/01 by Ausimont Co.) with low-molecular weight which is long wearing and comfortable (excellent) to use. This PPIE was adsorbed more than 90% in this experinient and formed the well-balanced gei nerworks even if the selected PP1E is 100% volutile ar room remperarure. On the basis of the adsorprion of FPIE, we developed rlie new type lipstick, whicli was highly-lip feeling and had long wearing and non coloration. And these cliaracreristics were verified by acrual consumer test.
Hyaluronic acid filler stimulates collagen neogenesis: case series of hand rejuvenation
( Sang Hyung Lee ),( Myoung Shin Kim ),( Hong Il Cho ),( Ki Young Park ),( Ji Hyun Lee ),( Jae Kyung Kim ),( Jong Heon Baek ),( Chong Hyun Won ),( Choon Shik Youn ),( Dong Hyun Kim ) 대한피부과학회 2015 대한피부과학회 학술발표대회집 Vol.67 No.1
The aging hands characterized by volume loss and changes in skin texture, resulting in thinning of skin and more visible wrinkles and vessels. This study was designed to estimate the clinical and biophysiologic effect of cross-linked hyaluronic acid (HA) filler on aging hand. Furthermore, we investigated whether this effect depends on the particle size of HA filler. 8 Korean patients (age 34-74) with signs of photoaging on both hands were recruited in this study. We injected two kinds of cross-linked HA fillers, 400um and 900um sized particle, intradermally in the dorsum of both hands and obtained biopsies after 4 and 12 weeks. No serious adverse events were reported during the 12-week follow up. We observed that injected materials remained in place in treated sites. All patients showed clinical improvement in wrinkles and volume loss on treated area. RT-PCR results showed increases at 4 weeks in relative expression of the procollagen I, collagen III and tissue inhibitors (TIMP-1) at the sites treated by filler (900 um particle size) compared with untreated sites. This effect was sustained for at least 12 weeks. Interestingly, there was no significant difference in the expression of the transcriptional markers for collagen neogenesis between particle size of 400 um and 900 um HA fillers injections, at 4-week in this study.
Cho, Young-Eun,Kim, Sang-Hyun,Lee, Byung-Heon,Baek, Moon-Chang The Korean Society of Applied Pharmacology 2017 Biomolecules & Therapeutics(구 응용약물학회지) Vol.25 No.4
This study was performed to evaluate whether microRNAs (miRNAs) in circulating exosomes may serve as biomarkers of drug-induced liver, kidney, or muscle-injury. Quantitative PCR analyses were performed to measure the amounts of liver-specific miRNAs (miR-122, miR-192, and miR-155), kidney-specific miR-146a, or muscle-specific miR-206 in plasma and exosomes from mice treated with liver, kidney or muscle toxicants. The levels of liver-specific miRNAs in circulating plasma and exosomes were elevated in acetaminophen-induced liver injury and returned to basal levels by treatment with antioxidant N-acetyl-cysteine. Circulating miR-146a and miR-206 were increased in cisplatin-induced nephrotoxicity and bupivacaine-induced myotoxicity, respectively. Taken together, these results indicate that circulating plasma and exosomal miRNAs can be used as potential biomarkers specific for drug-induced liver, kidney or muscle injury.
Cho, Sun Young,Oh, Seung Hwan,Suh, Jin-Tae,Lee, Hee Joo,Lee, Woo-In,Baek, Sun Kyung,Cho, Kyung Sam,Park, Tae Sung S. Karger AG 2011 Acta haematologica Vol.126 No.2
<P>Abstract</P><P>No abstract available</P><P>Copyright © 2010 S. Karger AG, Basel</P>